Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment of different diseases including cancer. They are composed of a ligand specifically binding to target cells genetically linked to a human apoptosis-inducing enzyme. hCFPs target cancer cells via an antibody or derivative (scFv) specifically binding to e.g., tumor associated antigens (TAAs). After internalization and translocation of the enzyme from endocytosed endosomes, the human enzymes introduced into the cytosol are efficiently inducing apoptosis. Under in vivo conditions such enzymes are subject to tight regulation by native inhibitors in order to prevent inappropriate induction of cell death in healthy cells. Tumor cells are known to upr...
Targeted therapies for the treatment of cancer, but also inflammation and autoimmune diseases will r...
Immunotoxins are fusion proteins that combine a targeting component such as an antibody fragment or ...
Immunotoxins are fusion proteins that combine a targeting component such as an antibody fragment or ...
Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment ...
Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment ...
Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment ...
Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment ...
The use of therapies based on antibody fusion proteins for the selective elimination of tumor cells ...
Targeted human cytolytic fusion proteins (hCFPs) represent a new generation of immunotoxins (ITs) fo...
Targeted human cytolytic fusion proteins (hCFPs) represent a new generation of immunotoxins (ITs) fo...
Human cytolytic fusion proteins (hCFPs) offer a promising immunotherapeutic approach for the treatme...
Immunotoxins are fusion proteins that combine a targeting component such as an antibody fragment or ...
Cancer immunotherapy aims to selectively target and kill tumor cells whilst limiting the damage to h...
Cancer immunotherapy aims to selectively target and kill tumor cells whilst limiting the damage to h...
Human cytolytic fusion proteins (hCFPs) are a new class of anti-cancer drugs that are usually less c...
Targeted therapies for the treatment of cancer, but also inflammation and autoimmune diseases will r...
Immunotoxins are fusion proteins that combine a targeting component such as an antibody fragment or ...
Immunotoxins are fusion proteins that combine a targeting component such as an antibody fragment or ...
Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment ...
Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment ...
Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment ...
Targeted human cytolytic fusion proteins (hCFPs) are humanized immunotoxins for selective treatment ...
The use of therapies based on antibody fusion proteins for the selective elimination of tumor cells ...
Targeted human cytolytic fusion proteins (hCFPs) represent a new generation of immunotoxins (ITs) fo...
Targeted human cytolytic fusion proteins (hCFPs) represent a new generation of immunotoxins (ITs) fo...
Human cytolytic fusion proteins (hCFPs) offer a promising immunotherapeutic approach for the treatme...
Immunotoxins are fusion proteins that combine a targeting component such as an antibody fragment or ...
Cancer immunotherapy aims to selectively target and kill tumor cells whilst limiting the damage to h...
Cancer immunotherapy aims to selectively target and kill tumor cells whilst limiting the damage to h...
Human cytolytic fusion proteins (hCFPs) are a new class of anti-cancer drugs that are usually less c...
Targeted therapies for the treatment of cancer, but also inflammation and autoimmune diseases will r...
Immunotoxins are fusion proteins that combine a targeting component such as an antibody fragment or ...
Immunotoxins are fusion proteins that combine a targeting component such as an antibody fragment or ...